Benzbromarone

Information about Benzbromarone

Benzbromarone is a nonpurine xanthine oxidase inhibitor used for the treatment of gout, but never approved for use in the United States because of concerns over reports of acute liver injury and deaths with its use.

Mechanism of action of Benzbromarone

Benzbromarone (benz broe' ma rone) is a nonpurine inhibitor of xanthine oxidase that shares no structural homology to allopurinol or to hypoxanthine, but rather is a structural homologue of amiodarone and dronedarone. Therapy leads to lowering of serum uric acid levels within a few weeks, and chronic therapy has been shown to decrease uric acid levels into target levels of less than 6 mg/dL and to decrease acute gouty attacks.

FDA approval information for Benzbromarone

Benzbromarone was approved for use in Europe and Asia, but was not licensed in the United States because of concerns over hepatotoxicity.

Withdrawn

Benzbromarone was withdrawn by its sponsor in 2003 because of continuing concerns over hepatotoxicity.

The following drugs are considered antigout medications:

• Allopurinol
• Benzbromarone
• Colchicine
• Febuxostat
• Lesinurad
• Pegloticase
• Probenecid
• Rasburicase

• Dailymed label info on Benzbromarone
• FDA Benzbromarone

Benzbromarone Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski